Neoplasm, Residual

16 treatments and conditions followed through the public trial records. Not medical advice.How a status is set

Lists this condition and the narrower ones beneath it. A condition is not a diagnosis.

Treatments and conditions

Neoplasm, Residual
Treatment and conditionWhere it standsTrials
Blinatumomab for neoplasm, residualPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)3
BLINATUMOMAB + Venetoclax for neoplasm, residualPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Circulating tumor DNA (ctDNA) testing + Datopotamab Deruxtecan for neoplasm, residualPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ELI-002 2P for neoplasm, residualPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Folfoxiri for neoplasm, residualPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
INCA33890 for neoplasm, residualTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
LENALIDOMIDE + Acalabrutinib + OBINUTUZUMAB for neoplasm, residualPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Low-Dose Radiation Therapy (LDRT) for neoplasm, residualTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
mFOLFOXIRI for neoplasm, residualTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Osimertinib for neoplasm, residualTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
RITUXIMAB + LENALIDOMIDE + Acalabrutinib for neoplasm, residualPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sugemalimab for neoplasm, residualPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
TAGRAXOFUSP + Azacitidine + Venetoclax for neoplasm, residualPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tisagenlecleucel for neoplasm, residualPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tki + blinatumomab for neoplasm, residualPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Zymosan + α-lactalbumin vaccine for neoplasm, residualPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1